Repositrak, Inc. (TRAK) - 10-Q Summary
Business Context and Reporting Period
Company: Repositrak, Inc. (formerly Park City Group, Inc.)
Reporting Period: Quarterly period ended December 31, 2025 (Fiscal Q2 2026)
Business Model: SaaS provider offering B2B e-commerce, compliance, traceability, and supply chain management platforms. The company operates a "hub and spoke" model, engaging retailers/wholesalers (Hubs) who mandate usage by their suppliers (Spokes).
Key Drivers: Growth is driven by regulatory mandates (FSMA 204) and retailer requirements for food traceability and safety compliance.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Revenue | $5,856,811 | $11,828,278 |
| Net Income | $1,686,040 | $3,505,569 |
| Net Income (Common Shareholders) | $1,639,489 | $3,400,201 |
| Diluted EPS | $0.09 | $0.18 |
| Operating Cash Flow (6mo) | $3,776,672 | |
| Cash & Equivalents (Dec 31, 2025) | $28,706,493 | |
| Total Debt | $403,843 (Financing Leases only; No bank debt) | |
| Working Capital | $28,549,189 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 7% year-over-year (YoY) for the quarter and 8% YoY for the six-month period. Growth is attributed to recurring subscription revenue across compliance, supply chain, and traceability lines.
- Profitability: Net income increased 9% YoY for the quarter ($1.69M vs $1.55M) and 9% YoY for the six months ($3.51M vs $3.22M).
- Cost Efficiency: Cost of revenue decreased 15% YoY for the quarter and 8% for the six months, primarily due to capitalizing development costs for platform enhancements. Gross margin improved from 18% to 15% of revenue (quarterly).
- Operating Expenses: Sales and marketing expenses rose 3% (quarterly) due to higher commissions and traceability marketing. General and administrative expenses rose 7% due to higher insurance and benefit costs.
- Capital Allocation: The company significantly increased share buybacks, repurchasing $1.25M of common stock in the six-month period. Preferred stock redemptions totaled $1.5M.
Guidance, Outlook, and Risks
- Regulatory Outlook: The FDA extended the FSMA 204 compliance deadline to July 2028. However, major retailers are mandating traceability requirements earlier (e.g., June 2025), driving immediate demand for Repositrak's services.
- Dividends: The Board declared a quarterly cash dividend of $0.02 per share (annualized $0.08), representing a ~0.65% yield. This is the third 10% increase since the dividend program began in 2022.
- Preferred Stock Redemption: The company intends to redeem all remaining Series B Preferred Stock (approx. $2.1M remaining) by December 2026.
- Interest Rate Risk: Management notes that Federal Reserve rate cuts may reduce future interest income on cash balances, though the company maintains a strong cash position ($28.7M).
- Legal/Contingencies: No material pending legal proceedings. No off-balance sheet arrangements.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 7-8% revenue growth given the extension of the FDA FSMA 204 deadline to 2028.
- Capitalization of Costs: Review the specific development costs capitalized to reduce Cost of Revenue, ensuring they meet GAAP criteria for software development.
- Share Count Dilution/Accretion: Monitor the impact of the ongoing $6.5M remaining share repurchase program against the issuance of shares for stock compensation and preferred stock conversions.
- Preferred Stock Liability: Confirm the timeline and cash impact of the remaining $2.1M Series B Preferred redemption obligation.
- Interest Income Sensitivity: Assess the impact of falling interest rates on the company's investment income, which contributed significantly to "Other Income."